Issue 6, 2017

The discovery of a potent Nav1.3 inhibitor with good oral pharmacokinetics

Abstract

In this article, we describe the discovery of an aryl ether series of potent and selective Nav1.3 inhibitors. Based on structural analogy to a similar series of compounds we have previously shown bind to the domain IV voltage sensor region of Nav channels, we propose this series binds in the same location. We describe the development of this series from a published starting point, highlighting key selectivity and potency data, and several studies designed to validate Nav1.3 as a target for pain.

Graphical abstract: The discovery of a potent Nav1.3 inhibitor with good oral pharmacokinetics

Article information

Article type
Research Article
Submitted
14 Mar 2017
Accepted
26 Apr 2017
First published
28 Apr 2017

Med. Chem. Commun., 2017,8, 1255-1267

The discovery of a potent Nav1.3 inhibitor with good oral pharmacokinetics

D. C. Pryde, N. A. Swain, P. A. Stupple, C. W. West, B. Marron, C. J. Markworth, D. Printzenhoff, Z. Lin, P. J. Cox, R. Suzuki, S. McMurray, G. J. Waldron, C. E. Payne, J. S. Warmus and M. L. Chapman, Med. Chem. Commun., 2017, 8, 1255 DOI: 10.1039/C7MD00131B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements